News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

September 9, 2021 Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
August 9, 2021 Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
July 29, 2021 Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
July 26, 2021 Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 7, 2021 Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
June 30, 2021 Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
June 23, 2021 Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
June 3, 2021 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
May 25, 2021 Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
May 14, 2021 Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)